<style>
.table-wrap{overflow:auto; max-width:100%;}
.segment-pivot { width:100%; border-collapse:collapse; font-family: Arial, sans-serif; font-size:14px; }
.segment-pivot thead th { position:sticky; top:0; background:#fff; z-index:1; border-bottom:1px solid #ddd; }
.segment-pivot th, .segment-pivot td { padding:6px 8px; border-bottom:1px solid #f0f0f0; }
.segment-pivot tbody tr:nth-child(even){ background:#fafafa; }
.segment-pivot td, .segment-pivot th { white-space:nowrap; }
.segment-pivot td { font-variant-numeric: tabular-nums; text-align:right; }
.segment-pivot td:first-child, .segment-pivot th:first-child { text-align:left; }
.table-note { font-size:12px; color:#666; margin:6px 0 8px; }
</style>
<div class="table-note">SEGMENTS v2025-09-09 · 2025-11-22 13:15 UTC — Units: <b>$B</b>. Rows list fiscal years (last 3 + TTM) with revenue and operating income for each segment; the final row shows the TTM revenue mix (operating income columns display “—” where mix is not applicable).</div>
<div class='table-wrap'><table class="dataframe segment-pivot">
  <thead>
    <tr style="text-align: right;">
      <th>Year</th>
      <th>Prod Rev</th>
      <th>Prod OI</th>
      <th>H I V Product Sales Rev</th>
      <th>H I V Product Sales OI</th>
      <th>H I V Products Biktarvy Rev</th>
      <th>H I V Products Biktarvy OI</th>
      <th>Oncology Product Rev</th>
      <th>Oncology Product OI</th>
      <th>Liver Disease Rev</th>
      <th>Liver Disease OI</th>
      <th>H I V Products Descovy Rev</th>
      <th>H I V Products Descovy OI</th>
      <th>Cell Therapy Products Total Cell Therapy Product Sales Rev</th>
      <th>Cell Therapy Products Total Cell Therapy Product Sales OI</th>
      <th>H I V Products Genvoya Rev</th>
      <th>H I V Products Genvoya OI</th>
      <th>Other Products Yescarta Rev</th>
      <th>Other Products Yescarta OI</th>
      <th>Royalty Contract And Other Rev</th>
      <th>Royalty Contract And Other OI</th>
      <th>Trodelvy Rev</th>
      <th>Trodelvy OI</th>
      <th>Liver Disease Products Sofosbuvir Velpatasvir Rev</th>
      <th>Liver Disease Products Sofosbuvir Velpatasvir OI</th>
      <th>H I V Products Odefsey Rev</th>
      <th>H I V Products Odefsey OI</th>
      <th>Liver Disease Products Vemlidy Rev</th>
      <th>Liver Disease Products Vemlidy OI</th>
      <th>Liver Disease Products Other Liver Disease Rev</th>
      <th>Liver Disease Products Other Liver Disease OI</th>
      <th>Other Products Total Other Product Sales Rev</th>
      <th>Other Products Total Other Product Sales OI</th>
      <th>Veklury Rev</th>
      <th>Veklury OI</th>
      <th>Other Products Am Bisome Rev</th>
      <th>Other Products Am Bisome OI</th>
      <th>H I V Products Symtuza Revenue Share Rev</th>
      <th>H I V Products Symtuza Revenue Share OI</th>
      <th>H I V Products Other H I V Rev</th>
      <th>H I V Products Other H I V OI</th>
      <th>Cell Therapy Products Tecartus Rev</th>
      <th>Cell Therapy Products Tecartus OI</th>
      <th>Other Products Other Rev</th>
      <th>Other Products Other OI</th>
      <th>Total Rev</th>
      <th>Total OI</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>2022</td>
      <td>80.9B</td>
      <td>0.00B</td>
      <td>34.4B</td>
      <td>0.00B</td>
      <td>20.8B</td>
      <td>0.00B</td>
      <td>4.28B</td>
      <td>0.00B</td>
      <td>5.60B</td>
      <td>0.00B</td>
      <td>3.74B</td>
      <td>0.00B</td>
      <td>2.92B</td>
      <td>0.00B</td>
      <td>4.81B</td>
      <td>0.00B</td>
      <td>2.32B</td>
      <td>0.00B</td>
      <td>0.90B</td>
      <td>0.00B</td>
      <td>1.36B</td>
      <td>0.00B</td>
      <td>3.06B</td>
      <td>0.00B</td>
      <td>2.94B</td>
      <td>0.00B</td>
      <td>1.69B</td>
      <td>0.00B</td>
      <td>0.85B</td>
      <td>0.00B</td>
      <td>1.89B</td>
      <td>0.00B</td>
      <td>7.81B</td>
      <td>0.00B</td>
      <td>0.99B</td>
      <td>0.00B</td>
      <td>1.06B</td>
      <td>0.00B</td>
      <td>1.06B</td>
      <td>0.00B</td>
      <td>0.60B</td>
      <td>0.00B</td>
      <td>0.90B</td>
      <td>0.00B</td>
      <td>184.9B</td>
      <td>0.00B</td>
    </tr>
    <tr>
      <td>2023</td>
      <td>80.8B</td>
      <td>0.00B</td>
      <td>36.4B</td>
      <td>0.00B</td>
      <td>23.7B</td>
      <td>0.00B</td>
      <td>5.86B</td>
      <td>0.00B</td>
      <td>5.57B</td>
      <td>0.00B</td>
      <td>3.97B</td>
      <td>0.00B</td>
      <td>3.74B</td>
      <td>0.00B</td>
      <td>4.12B</td>
      <td>0.00B</td>
      <td>3.00B</td>
      <td>0.00B</td>
      <td>0.55B</td>
      <td>0.00B</td>
      <td>2.12B</td>
      <td>0.00B</td>
      <td>3.07B</td>
      <td>0.00B</td>
      <td>2.70B</td>
      <td>0.00B</td>
      <td>1.72B</td>
      <td>0.00B</td>
      <td>0.77B</td>
      <td>0.00B</td>
      <td>1.72B</td>
      <td>0.00B</td>
      <td>4.37B</td>
      <td>0.00B</td>
      <td>0.98B</td>
      <td>0.00B</td>
      <td>1.06B</td>
      <td>0.00B</td>
      <td>0.80B</td>
      <td>0.00B</td>
      <td>0.74B</td>
      <td>0.00B</td>
      <td>0.73B</td>
      <td>0.00B</td>
      <td>188.5B</td>
      <td>0.00B</td>
    </tr>
    <tr>
      <td>2024</td>
      <td>85.8B</td>
      <td>0.00B</td>
      <td>39.2B</td>
      <td>0.00B</td>
      <td>26.8B</td>
      <td>0.00B</td>
      <td>6.58B</td>
      <td>0.00B</td>
      <td>6.04B</td>
      <td>0.00B</td>
      <td>4.22B</td>
      <td>0.00B</td>
      <td>3.95B</td>
      <td>0.00B</td>
      <td>3.52B</td>
      <td>0.00B</td>
      <td>3.14B</td>
      <td>0.00B</td>
      <td>0.43B</td>
      <td>0.00B</td>
      <td>2.63B</td>
      <td>0.00B</td>
      <td>3.19B</td>
      <td>0.00B</td>
      <td>2.58B</td>
      <td>0.00B</td>
      <td>1.92B</td>
      <td>0.00B</td>
      <td>0.93B</td>
      <td>0.00B</td>
      <td>1.78B</td>
      <td>0.00B</td>
      <td>3.60B</td>
      <td>0.00B</td>
      <td>1.06B</td>
      <td>0.00B</td>
      <td>1.18B</td>
      <td>0.00B</td>
      <td>0.87B</td>
      <td>0.00B</td>
      <td>0.81B</td>
      <td>0.00B</td>
      <td>0.71B</td>
      <td>0.00B</td>
      <td>201.1B</td>
      <td>0.00B</td>
    </tr>
    <tr>
      <td>TTM</td>
      <td>85.1B</td>
      <td>0.00B</td>
      <td>41.2B</td>
      <td>0.00B</td>
      <td>28.7B</td>
      <td>0.00B</td>
      <td>6.42B</td>
      <td>0.00B</td>
      <td>6.36B</td>
      <td>0.00B</td>
      <td>5.34B</td>
      <td>0.00B</td>
      <td>3.63B</td>
      <td>0.00B</td>
      <td>3.03B</td>
      <td>0.00B</td>
      <td>2.96B</td>
      <td>0.00B</td>
      <td>2.79B</td>
      <td>0.00B</td>
      <td>2.79B</td>
      <td>0.00B</td>
      <td>2.50B</td>
      <td>0.00B</td>
      <td>2.29B</td>
      <td>0.00B</td>
      <td>2.18B</td>
      <td>0.00B</td>
      <td>1.68B</td>
      <td>0.00B</td>
      <td>1.52B</td>
      <td>0.00B</td>
      <td>1.24B</td>
      <td>0.00B</td>
      <td>0.99B</td>
      <td>0.00B</td>
      <td>0.98B</td>
      <td>0.00B</td>
      <td>0.87B</td>
      <td>0.00B</td>
      <td>0.67B</td>
      <td>0.00B</td>
      <td>0.54B</td>
      <td>0.00B</td>
      <td>203.8B</td>
      <td>0.00B</td>
    </tr>
    <tr>
      <td>% of Total (TTM)</td>
      <td>41.8%</td>
      <td>—</td>
      <td>20.2%</td>
      <td>—</td>
      <td>14.1%</td>
      <td>—</td>
      <td>3.1%</td>
      <td>—</td>
      <td>3.1%</td>
      <td>—</td>
      <td>2.6%</td>
      <td>—</td>
      <td>1.8%</td>
      <td>—</td>
      <td>1.5%</td>
      <td>—</td>
      <td>1.5%</td>
      <td>—</td>
      <td>1.4%</td>
      <td>—</td>
      <td>1.4%</td>
      <td>—</td>
      <td>1.2%</td>
      <td>—</td>
      <td>1.1%</td>
      <td>—</td>
      <td>1.1%</td>
      <td>—</td>
      <td>0.8%</td>
      <td>—</td>
      <td>0.7%</td>
      <td>—</td>
      <td>0.6%</td>
      <td>—</td>
      <td>0.5%</td>
      <td>—</td>
      <td>0.5%</td>
      <td>—</td>
      <td>0.4%</td>
      <td>—</td>
      <td>0.3%</td>
      <td>—</td>
      <td>0.3%</td>
      <td>—</td>
      <td>100%</td>
      <td>—</td>
    </tr>
  </tbody>
</table></div>